At ASMS 2012, Bruker announces the launch of the new ultrafleXtreme™
MALDI TOF/TOF system. Bruker’s market leading, top of the range product
has been significantly enhanced to offer both increased analytical power
and entirely new functionality, extending the applications envelope of
MALDI TOF/TOF far beyond the conventional concepts of what’s possible in
molecular histology, glycoprotein and biopharmaceuticals analysis.
(Photo: Business Wire)
Already the acknowledged leader in Mass Spectrometry Imaging (MSI), the
next-generation ultrafleXtreme system incorporates the
Bruker patented smartbeam™ laser, now with up to 2 kHz
repetition rate with true-pixel image resolution at 20µm for proteins.
This development marks a new milestone in the pioneering smartbeam
laser technology, designed and manufactured exclusively by Bruker for
unmatched performance in MALDI mass spectrometry.
While biomarker discovery in large tissue-sample cohorts can now be
achieved at record high speed, Bruker has also significantly extended
the discovery potential of Molecular Histology with the new ImageID™
workflow. The proprietary ImageID workflow is a
fully-integrated process to provide scientists with integrated tissue
maps for both protein distribution and identification. More than 100
proteins are typically characterized by the ImageID
workflow, where consecutive histological sections are processed in
parallel to generate complementary datasets in a single software
environment for comprehensive analysis. ImageID yields
identifications of approximately 80% of all peptides observed in imaging
measurements, also those derived from high molecular weight proteins.
For the first time, the method can access fixed (FFPE) tissue, allowing
molecular histology to be applied to vast collections of archived
clinical samples to unlock a potential treasure chest of biomarker data
in cancer studies.
The ultrafleXtreme has also become the industry
trendsetter in tools for biopharmaceutical characterization with
patented Top-Down T3-Sequencing
for revealing terminal modifications, post-translational modifications
(PTMs) and sequence impurities. Bruker now presents its rapidly
expanding biologics customer base with high resolution intact
biomolecule analysis on the new ultrafleXtreme platform.
The new MALDI-TOF/TOF system leaps across the conventional boundary
between MALDI and electrospray ionization by generating multiply-charged
intact protein ions for measurements with mass resolution of greater
than 30,000, which can yield isotopic information for 30 kDa proteins,
and larger protein molecular weight assignments with better than 15 ppm
mass accuracy. Achieved using the new ultrafleXtreme FlashDetector™
and DHAP matrix innovations, this intact protein bioanalytical ability
represents a paradigm change for biologics discovery, development and QC.
The ultrafleXtreme’s utility for the biopharmaceutical
industry and life-science research is further enhanced by Bruker’s new GlycoQuest™
glycan search engine which retrieves glycan structure candidates with
unprecedented ease, enabling expert full glycoprotein structure
elucidation for every molecular biologist.
“Precise intact biomolecule data at the speed and simplicity of MALDI
analysis with full glyco-structure reporting really completes the
picture for our biopharma customers,” commented Dr. Laura Main, Bruker
Daltonics’ Biopharmaceutical Market Manager.
About Bruker Corporation
Bruker Corporation (NASDAQ: BRKR) is a leading provider of
high-performance scientific instruments and solutions for molecular and
materials research, as well as for industrial and applied analysis. For
more information, please visit www.bruker.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50283564&lang=en
